Abstract:Despite early diagnosis, 10-20% of breast cancer patients experience metastatic disease within 5-10 years. While it is established that breast cancer cells have the capacity to evade immune responses, the mechanisms driving this evasion remain elusive. Therefore, finding ways to enhance anti-tumor immunity is crucial to improve patient outcomes. Dickkopf-1 (DKK1) is a Wnt inhibitor whose levels correlate with poor prognosis and decreased immune infiltration in various cancers. In this study, we used mice orthotopically injected with the PyMT, EO771, and 4T1 breast cancer lines. In all models, we found elevated DKK1 serum levels, and its neutralization with an αDKK1 Ab resulted in a significant reduction in primary tumor growth but also in metastatic dissemination. To identify the source of DKK1, we examined its expression in the tumor. DKK1 was detected in stromal cells with a fibroblast-like morphology but not in cancer cells or immune infiltrates. Co-staining confirmed colocalization between DKK1 and the CAF marker αSMA. To address the role of CAF-derived DKK1, we specifically deleted DKK1 in CAFs by generating FSP1CreDkk1fl/fl and αSMACreERT2Dkk1fl/fl mice. Both models showed a significant reduction in primary tumor growth while maintaining comparable serum DKK1 levels, indicating locally produced DKK1 supports tumor growth. To understand how DKK1 promotes tumor progression, we conducted bulk RNAseq of tumor cells isolated from IgG or αDKK1 treated mice. While no changes related to cell viability or cell cycle were observed, immune response-related genes were upregulated in αDKK1-treated cells. In support of this, αDKK1 did not reduce tumor growth in NSG immune-compromised mice. To pinpoint the immune cell targeted by DKK1, we depleted T, NK cells, or macrophages in WT tumor-bearing mice treated with αDKK1. Remarkably, only NK cell depletion negated αDKK1 anti-tumor effects. In vitro assays further demonstrated that rDKK1 or the presence of CAFs reduced NK cell cytotoxicity against tumor cells while αDKK1 restored it. To assess whether DKK1 levels correlated with tumor progression and immune suppression in breast cancer patients, we analyzed DKK1 serum levels and circulating NK cells at the diagnosis of metastatic bone disease and 15-18 months after standard care. DKK1 levels were significantly elevated in patients with progressive bone disease compared to those with stable disease. Importantly, NK cells from the progressive disease cohort had reduced perforin and granzyme B expression at the follow-up visit compared to baseline, indicating reduced cytotoxicity. Furthermore, rDKK1 reduced perforin in NK cells from healthy donors. In sum, our data show DKK1 is an important regulator of breast cancer progression, and we report for the first time DKK1 directly impairs NK cell cytotoxicity, creating an immune suppressive environment resistant to treatment. Citation Format: Seunghyun Lee, Biancamaria Ricci, Roberta Faccio. Cancer-associated fibroblast-derived Dickkopf-1 impairs anti-tumor immunity in breast cancer by suppressing NK cell-mediated cytotoxicity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 3925.

DKK1 drives immune suppressive phenotypes in intrahepatic cholangiocarcinoma and can be targeted with anti‐DKK1 therapeutic DKN‐01

Dickkopf-1: A Promising Target for Cancer Immunotherapy

High Expression of Dickkopf‐related Protein 1 is Related to Lymphatic Metastasis and Indicates Poor Prognosis in Intrahepatic Cholangiocarcinoma Patients after Surgery

940 Targeting DKK1 to Reverse Immunosuppressive Macrophages and Enhance PD-1 Blockade Therapy in Gastric Cancer

Dickkopf-1 drives tumor immune evasion by inducing PD-L1 expression in hepatocellular carcinoma

1382 DKK1 is a biomarker and immunotherapeutic target for bone metastases in malignant cancers

Abstract 5793: Functional DKK1 antibodies binding to cysteine-rich domain 1 or 2 of hDKK1 demonstrate antagonistic activities on tumor suppression or TCF/LEF signaling

Supplementary Data from DKK1 Promotes Tumor Immune Evasion and Impedes Anti–PD-1 Treatment by Inducing Immunosuppressive Macrophages in Gastric Cancer

DKK1 promotes hepatocellular carcinoma inflammation, migration and invasion: Implication of TGF-β1

DKK1 Affects Survival of Patients with Head and Neck Squamous Cell Carcinoma by Inducing Resistance to Radiotherapy and Immunotherapy

Abstract 3925: Cancer-associated fibroblast-derived Dickkopf-1 impairs anti-tumor immunity in breast cancer by suppressing NK cell-mediated cytotoxicity

CK1δ in Lymphoma: Gene Expression and Mutation Analyses and Validation of CK1δ Kinase Activity for Therapeutic Application.

CDK9 inhibitors downregulate DKK1 expression to suppress the metastatic potential of HCC cells

Dickkopf-1 (DKK1) promotes invasion and metastasis of hepatocellular carcinoma

Effects of Altered Expression and Activity Levels of CK1δ and Ɛ on Tumor Growth and Survival of Colorectal Cancer Patients

Dickkopf-1 (DKK1) drives growth and metastases in castration-resistant prostate cancer

Rationale for targeting the Wnt signalling modulator Dickkopf-1 for oncology

DKK1 as a chemoresistant protein modulates oxaliplatin responses in colorectal cancer

Evolving functions of Dickkopf-1 in cancer and immunity

Overexpression of Dickkopf-1 Predicts Poor Prognosis for Patients with Hepatocellular Carcinoma after Orthotopic Liver Transplantation by Promoting Cancer Metastasis and Recurrence

Combination therapy of DKK1 inhibition and NKG2D chimeric antigen receptor T cells for the treatment of gastric cancer